A5050367365- Dermatology and Skin Diseases
- Immunodeficiency and Autoimmune Disorders
- Autoimmune and Inflammatory Disorders
- Urticaria and Related Conditions
- Cutaneous Melanoma Detection and Management
- Vascular Malformations and Hemangiomas
- Autoimmune Bullous Skin Diseases
- Medicine and Dermatology Studies History
- IL-33, ST2, and ILC Pathways
- Oral Health Pathology and Treatment
- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- Hidradenitis Suppurativa and Treatments
- Parvovirus B19 Infection Studies
- Parathyroid Disorders and Treatments
- Exercise and Physiological Responses
- Genetic factors in colorectal cancer
- Eosinophilic Disorders and Syndromes
- Medicine, History, and Philosophy
- Tumors and Oncological Cases
- History of Education in Spain
- Vascular Malformations Diagnosis and Treatment
- Contact Dermatitis and Allergies
- Chemotherapy-related skin toxicity
- Soft tissue tumors and treatment
Centre Hospitalier Universitaire de Besançon
2010-2024
Inserm
2024
Université de Bourgogne
2024
Rockefeller University
2024
Hôpital Privé Jean Mermo
2020
The long-term effectiveness of immune checkpoint inhibitor (ICI) rechallenge for progressive or recurrent advanced melanoma following previous disease control induced by ICI has not been thoroughly described in the literature.In this retrospective multicenter national real-life study, we enrolled patients who had rechallenged with an after achieving a first course ICI, which was subsequently interrupted. primary objective to evaluate tumor response, while secondary objectives included...
Abstract is missing (Short communication)
9529 Background: The efficacy of ICI rechallenge for progressive/recurrent disease advanced melanoma patients (pts) after a first course interrupted control has not been systematically described. Methods: A retrospective observational multicenter national real-life study evaluated the and tolerance (anti-PD1, anti-CTLA-4, or combination therapy) in pts who progressed with an subsequently interrupted. Primary objective was to evaluate tumor response using RECIST version 1.1. Secondary...